title: [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey].
abstract: Hypertrophic cardiomyopathy (HCM) is a relatively common disease of the cardiac sarcomere with broad heterogeneity in terms of the disease-causing gene mutation, phenotypic expression, therapy and prognosis. Besides the standard drug treatment, there are several therapeutic options available for severe refractory symptomatic HCM with obstruction. Dual-chamber pacing and transcoronary ablation of septal hypertrophy (TASH) have recently emerged as alternatives to myectomy. However, myectomy remains the current gold standard of therapy for HCM until the promising initial follow-up data for TASH can be transferred into a long-term follow-up period, or prospective randomized comparative trials between these therapies are available. However, even now, TASH represents an important therapeutic alternative in patients with relevant co-morbidities and a high operative risk. Despite significant gradient reduction and amelioration of clinical symptoms, none of these treatment strategies has a proven influence on the natural history of HCM. Hence, regarding the long-term prognosis of the disease, risk stratification of sudden cardiac death using non-invasive risk assessment has become of paramount importance, while genotyping might become the determinant and stratifying marker in the near future. At present, according to secondary prevention, treatment with an implanted cardioverter-defibrillator +/- amiodarone therapy is mandatory, while according to primary prevention treatment should particularly depend on the individual risk profile.
authors.affiliation: Medizinische Klinik I, Klinikum Krefeld, Lutherplatz 40, 47805 Krefeld, Germany. sereith@gmx.de
authors.forename: S
authors.initials: S
authors.lastname: Reith
authors.forename: H G
authors.initials: HG
authors.lastname: Klues
mesh_terms: D002312:Cardiomyopathy, Hypertrophic / Q000145:classification / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods / Q000401:mortality; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control; D017147:Defibrillators, Implantable; D006346:Heart Septum / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D019060:Minimally Invasive Surgical Procedures; D010138:Pacemaker, Artificial; D015996:Survival Rate; D014694:Ventricular Outflow Obstruction / Q000145:classification / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*
chemical_list: D002317:Cardiovascular Agents
vernacular_title: Therapie und Risikostratifizierung der Hypertrophen Kardiomyopathie. Ein aktueller Uberblick.